Labiotech.eu

f2g fungal infections antifungals aspergillosis

News and Trends 22 Jun 2016

Massive Round: Novel Antifungals get €53M from Top-Notch Investors

F2G has raised €53M to advance its news class of treatments for life-threatening fungal infections, including invasive aspergillosis. The technology has attracted some of the major biotech investors in Europe. Based in Manchester (UK), F2G focuses on developing therapies for invasive fungal infections such as aspergillosis. This type of infections mostly affect patients that are […]

June 22, 2016 - 2 minutesmins - By Denise Neves Gameiro

Best in Biotech 22 Jun 2016

11 Biotech Leaders you should meet in Munich

I guess you’ve read some of our tops lately (VCs, Paris, Unicorns). Those were mainly about specific companies or regions. Now, we wanted to try a new format and focus on people instead. For this first edition, we decided to focus on Munich, one of Europe’s top biotech regions. I asked some biotech leaders in Munich […]

June 22, 2016 - 5 minutesmins - By Philip Hemme

circassia cat grass allergy toleromune spire

News and Trends 21 Jun 2016

Allergy Immunotherapy Knocked Out in Phase III by an ‘Overperforming Placebo’

Circassia’s pipeline takes a major step back as its therapy for cat allergy gets disappointing results — it had the same effect as the placebo. Stocks promptly sank by 65%. The Oxford-based Circassia has been a major European player in the field of allergy immunotherapies. It made a splash when it raised €267.7M in the London Stock […]

June 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

labiotech refresh microbiome isabelle cremoux

News and Trends 21 Jun 2016

“The Microbiome will be as big as Biotech in 10 Years”

Isabelle de Cremoux, the CEO of Seventure Partners, was at Labiotech Refresh to tell us when and how she fell in love with the microbiome and what the future holds for this exciting field. De Cremoux is the person behind Seventure, one of the top European VCs and the first in the world to focus mainly […]

June 21, 2016 - 4 minutesmins - By Denise Neves Gameiro

astrazeneca asthma copd epigenetic targets

News and Trends 21 Jun 2016

UK Partnership is looking for new Epigenetic targets in Respiratory Disease

AstraZeneca and MRC Technology are launching an initiative to find new epigenetic targets in respiratory disease. By picking promising academic research, the two parties expect to lock in new drugs for diseases like asthma. After partnering up with genomics elite for a new biobank, AstraZeneca is again preparing to tap into collaborations with academia. This […]

June 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 20 Jun 2016

GMO Tobacco could Produce cheaper Medicine for Malaria

Researchers from the Max Planck Institute of Molecular Plant Physiology in Potsdam have altered tobacco to produce large yields of artemisinin – the most effective treatment for malaria but still without a cheap and reliable source. Artemisinin is used in the most effective treatments against malaria, the discovery of which was worth a Nobel Prize. […]

June 20, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 20 Jun 2016

I tried the Amazon for labs, and it makes life way easier!

Ordering a kit for an experiment could quickly become a nightmare. There are an incredible amount of suppliers out there who are selling similar products that could greatly vary in price and quality. Finding a neutral review on these products is also quite hard as all available references tend to be made by suppliers themselves. Have […]

June 20, 2016 - 4 minutesmins - By Joachim Eeckhout

curetis blood infection diagnostic pathogen resistance

News and Trends 20 Jun 2016

This Sepsis Detection Test saves 24h for Faster Treatment

Curetis has received great results for its diagnostic kit. This new technology to detect sepsis is delivering the same results as standard tests, but it’s faster by 24 hours – critical time to deal with life-threatening infections. Based in Stuttgart (Germany), Curetis was the only German biotech to do an IPO in 2015. It did so with a bang, […]

June 20, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 20 Jun 2016

Meet the Biotech successfully using Bacteria for Immuno-Oncology

Yes, the title may have surprised you, but it’s true. Vaximm is one of the few biotechs worldwide using bacteria to activate the immune system against cancer. I was really surprised about how elegant the technology is when I had a chat with the Executive Chairman Klaus Breiner at BioEquity in Copenhagen. Vaximm is based in Basel […]

June 20, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 17 Jun 2016

After its drop earlier this year, Genticel goes back up the slope

Genticel has announced that not one but two milestones have been achieved in the development of its products, which focus on immunotherapies for cancers caused by the human papillomavirus. Genticel is developing GTL001 (named ProCervix in Europe) to answer an unmet medical need – the eradication of the virus HPV 16 or 18 (high-risk types that […]

June 17, 2016 - 3 minutesmins - By Jerome Topsent

News and Trends 17 Jun 2016

Apogenix’s lead Candidate has more than one Trick up its Sleeve

Apogenix‘s lead candidate APG101, which has shown great results in a phase II study to treat Glioblastoma, has a new target in line. But this time, it’s not against cancer… Apogenix is a Germany-based company developing innovative immuno-oncology therapeutics for cancer and other malignant diseases. It was founded in 2005 and has raised over €90M […]

June 17, 2016 - 3 minutesmins - By Jerome Topsent

News and Trends 17 Jun 2016

Effective anti-infectives for medically unmet diseases? Ask Novabiotics

Toulouse was fun, but it’s time to go somewhere new! Fan of the Highlands, the landscapes that made the Harry Potter scenery much more exciting and the Loch Ness Monster? I’m just asking because this week we are going to Scotland! Aberdeen is our final destination, and we are visiting Novabiotics, our Biotech of the […]

June 17, 2016 - 2 minutesmins - By Joachim Eeckhout

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Massive Round: Novel Antifungals get €53M from Top-Notch Investors

11 Biotech Leaders you should meet in Munich

Allergy Immunotherapy Knocked Out in Phase III by an ‘Overperforming Placebo’

“The Microbiome will be as big as Biotech in 10 Years”

UK Partnership is looking for new Epigenetic targets in Respiratory Disease

GMO Tobacco could Produce cheaper Medicine for Malaria

I tried the Amazon for labs, and it makes life way easier!

This Sepsis Detection Test saves 24h for Faster Treatment

Meet the Biotech successfully using Bacteria for Immuno-Oncology

After its drop earlier this year, Genticel goes back up the slope

Apogenix’s lead Candidate has more than one Trick up its Sleeve

Effective anti-infectives for medically unmet diseases? Ask Novabiotics

Subscribe to our newsletter to get the latest biotech news!